Authored by Karl Simpson
Another Day Completed, Another Deal Concluded for an Antibody Drug Conjugates. The antibody market is clearly nothing new but there is renewed focus in the potential of full humanised antibodies and Antibody Drug Conjugates (ADCs). Seattle Genetics have been a key innovator of the ADC, along with ImmunoGen, and this week Seattle Genetics have announced a subsequent partnership with Bayer which has the potential to garner as much as $520m for Seattle.
This is not Seattle Genetics first alliance, it has multiple deals established for its ADC technology with many of the hallmark pharmaceutical companies, not least Takeda with whom they have a deal for Adcetris, a product indicated for lymphoma.
Through the deal, Bayer will pay up to $20m in an upfront payment to gain global rights to use the company’s auristatins with antibodies against unspecified cancer targets. This deal supplements a broader antibody drug conjugate programme being pursued by the pharma giant, Bayer. The subsequent $500m in the deal is gained once milestones have been reached and royalties realised from products sold across the world emanating from the partnering deal.
Seattle Genetics is really on a roll right now and their technology for ADCs is clearly in demand. They had a great ASCO this year and their partnership with Roche seems to be bringing some success too, with the FDA approval earlier this year of Kadcyla, which came from the Seattle Genetics technology.
With such an array of partnerships and very many candidates in clinical stage development, the future for Seattle Genetics looks highly promising and it certainly seems to be stoking interest in Antibody Drug Conjugates more broadly.